SWOG clinical trial number
CTSU/R1306
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Closed
Phase
Abbreviated Title
Rand Ph II, Individualized Combined Modality, Stage III NSCLC
Status Notes
This study closed to accrual on 12/20/17.
Activated
09/01/2013
Closed
12/20/2017
Participants
CTSU
Research committees
Lung Cancer
Treatment
Radiation Therapy
Erlotinib
Crizotinib
Other Clinical Trials
SWOG Clinical Trial Number
A082302
EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409
PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231
A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase